Literature DB >> 9224818

Development of resistance of human immunodeficiency virus type 1 to dextran sulfate associated with the emergence of specific mutations in the envelope gp120 glycoprotein.

J A Este1, D Schols, K De Vreese, K Van Laethem, A M Vandamme, J Desmyter, E De Clercq.   

Abstract

Polyanionic compounds are known to inhibit the binding of human immunodeficiency virus (HIV) to CD4+ cells and the subsequent fusion step between the virus and cells. We selected an HIV-1 strain resistant to dextran sulfate (DS) by cultivation of HIV-1 (NL4-3)-infected MT-4 cells in the presence of DS Mr 5000. DS did not inhibit the binding of DS-resistant virus to MT-4 cells or syncytium formation between MOLT cells and HUT-78 cells persistently infected with the DS-resistant virus. In addition, a monoclonal antibody with specificity for the V3 loop of envelope gp120 glycoprotein did not recognize the DS-resistant HIV-1 gp120 V3 loop. The following mutations were found in the gp120 molecule of the DS-resistant HIV-1 strain but not in the wild-type strain: S114N in the V1 loop region; S134N in the V2 loop region; K269E, Q278H, and N293D in the V3 loop region; N323S in the C3 region; a deletion of five amino acids (Phe-Asn-Ser-Thr-Trp) at positions 364-368 in the V4 loop; and R3871 in the CD4 binding domain. Our results suggest that (i) DS interacts with specific amino acid residues in the gp120 molecule, (ii) the virus is able to overcome the inhibitory effect of DS on viral infectivity, (iii) cross-resistance developed against those polyanionic compounds that are structurally related to DS, and (iv) the molecular determinants of HIV cell tropism, syncytium-inducing ability, coreceptor (fusin/ CC-CKR5) utilization, and polyanion resistance seem to be located in the env genome of HIV and specifically in the V3 loop domain.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9224818     DOI: 10.1124/mol.52.1.98

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  22 in total

1.  ADS-J1 inhibits HIV-1 entry by interacting with gp120 and does not block fusion-active gp41 core formation.

Authors:  Emmanuel González-Ortega; Maria-Pau Mena; Marc Permanyer; Ester Ballana; Bonaventura Clotet; José A Esté
Journal:  Antimicrob Agents Chemother       Date:  2010-07-19       Impact factor: 5.191

2.  Critical design features of phenyl carboxylate-containing polymer microbicides.

Authors:  Robert F Rando; Sakae Obara; Mark C Osterling; Marie Mankowski; Shendra R Miller; Mary L Ferguson; Fred C Krebs; Brian Wigdahl; Mohamed Labib; Hiroyasu Kokubo
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

3.  Mutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp41 and Rev-responsive element functions.

Authors:  Daisuke Nameki; Eiichi Kodama; Mieko Ikeuchi; Naoto Mabuchi; Akira Otaka; Hirokazu Tamamura; Mutsuhito Ohno; Nobutaka Fujii; Masao Matsuoka
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

4.  T-cell-line-tropic human immunodeficiency virus type 1 that is made resistant to stromal cell-derived factor 1alpha contains mutations in the envelope gp120 but does not show a switch in coreceptor use.

Authors:  D Schols; J A Esté; C Cabrera; E De Clercq
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

5.  Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120.

Authors:  M Moulard; H Lortat-Jacob; I Mondor; G Roca; R Wyatt; J Sodroski; L Zhao; W Olson; P D Kwong; Q J Sattentau
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

6.  Inhibition of coreceptor-independent cell-to-cell human immunodeficiency virus type 1 transmission by a CD4-immunoglobulin G2 fusion protein.

Authors:  Berta Bosch; Julià Blanco; Eduardo Pauls; Imma Clotet-Codina; Mercedes Armand-Ugón; Boyan Grigorov; Delphine Muriaux; Bonaventura Clotet; Jean-Luc Darlix; José A Esté
Journal:  Antimicrob Agents Chemother       Date:  2005-10       Impact factor: 5.191

7.  Phosphorothioate oligonucleotides inhibit human immunodeficiency virus type 1 fusion by blocking gp41 core formation.

Authors:  Andrew Vaillant; Jean-Marc Juteau; Hong Lu; Shuwen Liu; Carol Lackman-Smith; Roger Ptak; Shibo Jiang
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

8.  Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4.

Authors:  J A Esté; C Cabrera; J Blanco; A Gutierrez; G Bridger; G Henson; B Clotet; D Schols; E De Clercq
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

9.  Mannose-specific plant lectins from the Amaryllidaceae family qualify as efficient microbicides for prevention of human immunodeficiency virus infection.

Authors:  Jan Balzarini; Sigrid Hatse; Kurt Vermeire; Katrien Princen; Stefano Aquaro; Carlo-Federico Perno; Erik De Clercq; Herman Egberink; Guy Vanden Mooter; Willy Peumans; Els Van Damme; Dominique Schols
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

10.  RhoA-derived peptide dimers share mechanistic properties with other polyanionic inhibitors of respiratory syncytial virus (RSV), including disruption of viral attachment and dependence on RSV G.

Authors:  Philip J Budge; Yeqiang Li; Judy A Beeler; Barney S Graham
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.